0
0
Indianapolis, USA – Eli Lilly and Company has released encouraging early data for orforglipron, an experimental oral medication aimed at weight loss and blood sugar management, potentially offering a pill-based alternative to popular injectable treatments.
The pharmaceutical giant announced that in early-stage studies, orforglipron demonstrated effectiveness in helping individuals with Type 2 diabetes lower their blood sugar levels and achieve weight loss. This development positions Lilly as a potential frontrunner in bringing the first GLP-1 agonist weight-loss treatment to market in pill form, according to reports from The Wall Street Journal.
GLP-1 (glucagon-like peptide-1) receptor agonists, such as the widely known Ozempic and Wegovy (from Novo Nordisk), have gained significant popularity for managing diabetes and promoting weight loss. However, their current availability is limited to injectable formats.
The prospect of an effective oral alternative is highly anticipated by both medical professionals and patients. “It really gives us an opportunity to reach many more patients than you can reach with an injectable,” Jeffrey Emmick, senior vice president of product development at Lilly Cardiometabolic Health, stated to The Wall Street Journal.
A pill version addresses several challenges associated with injectables. Many patients prefer oral medication over injections, and pills typically do not require refrigeration, unlike many injectable drugs. This could significantly improve accessibility for patients globally, particularly in regions where consistent refrigeration is challenging. Furthermore, oral medications might be easier to manufacture at scale, potentially mitigating the shortages experienced shortly after Lilly launched its injectable GLP-1 drug.
The recent study results involved adults with Type 2 diabetes over a 40-week period. Participants receiving the highest dose of orforglipron experienced an average weight loss of 16 pounds, equating to approximately 7.9% of their initial body weight. Eli Lilly reported that the most common side effects were gastrointestinal (stomach-related) and were predominantly mild to moderate in severity.
Orforglipron works by targeting the GLP-1 hormone, which plays a role in regulating blood sugar and appetite. Unlike existing injectable GLP-1 drugs derived from large molecules (peptides), orforglipron is a small molecule drug. The Wall Street Journal noted that this structural difference might allow for easier absorption by the body when taken orally.
Eli Lilly aims to submit orforglipron for regulatory approval as a weight-loss treatment by the end of 2025, with submission for Type 2 diabetes treatment planned for 2026.
The development comes amidst fierce competition in the rapidly expanding obesity drug market, which experts project could surpass $100 billion by the end of the decade. Other pharmaceutical companies, including Novo Nordisk and Pfizer, are also actively developing their own oral GLP-1 treatments.
Disclaimer: This article is based on preliminary study results and information released by Eli Lilly. Orforglipron is an experimental drug currently undergoing clinical trials. It has not yet been approved by regulatory agencies such as the Food and Drug Administration (FDA) or other global health authorities for general use. The safety and efficacy profile will be further evaluated in larger, ongoing studies and during the regulatory review process. Consult with a healthcare professional for medical advice and treatment options.
